The $114 Billion Gut Feeling

In March 2025, PepsiCo wrote a cheque for $1.95 billion to buy a soda company that puts apple cider vinegar in sparkling water.

$1.95, with a B.

A month earlier, Coca-Cola launched Simply Pop, its first prebiotic soda.

A week before that, Olipop closed a $50 million Series C at a $1.85 billion valuation.

The company had $400 million in revenue.

It was profitable.

It had turned down both Coke and Pepsi.

In Auckland, a startup called Moodi is claiming 300% YOY growth selling pre+probiotic powder to women on TikTok. They make it in Whangaparaoa. Their tubs are made from sugarcane plastic. They have fewer than 50 employees.

The global probiotics market hit $114 billion in 2025. Gut health product launches jumped 61% between 2024 and 2025 alone. The digestive health supplement market is forecast to nearly double to $29 billion by 2033. Everyone from PepsiCo to a husband-and-wife team in a North Shore garage is selling your gut back to you.

The question is the same as always: what does it actually cost, who actually makes the money, and who wins when the dust settles?

The Claim

The gut health category has fragmented into five distinct product formats: drinks (kombucha, prebiotic soda, probiotic shots), powders (Moodi, AG1), gummies, capsules, and functional foods. Each format has wildly different unit economics. Different COGS. Different margins. Different distribution requirements. Different velocity profiles.

But the pattern playing out is the same one that plays out in every consumer category. Two or three brands consolidate the mainstream. Everyone else either gets acquired, niches down, or dies. PepsiCo just bought Poppi. Coca-Cola launched Simply Pop. Olipop is the last major independent. The prebiotic soda war is already a three-player game backed by two of the largest companies on earth.

The interesting question isn't who wins that war. It's where the white space is for everyone else. Because in gut health, unlike most consumer categories, the format you choose determines your entire business model. And some formats are structurally better than others.

A Brief History of Selling Your Gut

Gut health is not new. The marketing of gut health is what's new.

Yakult launched in 1935. A Japanese scientist named Minoru Shirota isolated a strain of Lactobacillus casei, put it in a tiny fermented milk drink, and started selling it door-to-door. Nearly 90 years later, Yakult sells 40 million bottles a day across 40 countries. The unit economics are beautiful: the product is tiny, shelf-stable, cheap to produce, and habitual. It is arguably the most successful gut health product ever made, and nobody on TikTok talks about it.

Danone figured it out next. Activia launched in 1987 as a probiotic yogurt, and by the mid-2000s it was a multi-billion dollar brand. The pitch was simple: eat yogurt, fix your digestion. It worked because yogurt was already a daily habit. Danone just bolted a health claim onto something people were already buying. Brilliant positioning. Mediocre science.

Then came the supplement era. Garden of Life, Culturelle, Align. Probiotic capsules in plastic bottles sold through pharmacies and health food stores. The unit economics were great for manufacturers (low COGS, high margin, shelf-stable), but the consumer experience was terrible. Nobody enjoys swallowing pills. Compliance rates are awful. And the Amazon marketplace turned probiotic capsules into a race to the bottom. Search "probiotic supplement" on Amazon and you'll find 10,000 results. Most of them indistinguishable. Most of them priced between $15 and $30 for a 30-day supply.

Kombucha was the first format to make gut health feel like a lifestyle choice rather than a medical one. We covered the kombucha economics in our previous piece. The short version: tea, sugar, water, SCOBY, time. Unit cost of $0.75 to $1.25. Retail of $3 to $14 depending on brand and scale. But kombucha has a structural problem: it needs refrigeration, it tastes like vinegar to half the population, and the production cycle is slow. It built the category. It won't dominate it.

The inflection point was 2018. That's the year both Olipop and Poppi launched. They asked a question nobody in the kombucha world had thought to ask: what if we made something that tastes like Coke, sits on a shelf at room temperature, and has prebiotics in it?

The format shift from kombucha to prebiotic soda is the entire story of this category. Fermentation was the proof of concept. Soda is the scale vehicle.

The Big Three: Olipop, Poppi, and Simply Pop

Olipop: The Independent That Said No

Ben Goodwin spent $300,000 of his own money developing probiotic sodas before Olipop existed. His first company, Obi, was a probiotic soda that launched in 2013 and failed. He sold it in 2016, licked his wounds, and started working on a new formula with co-founder David Lester.

Olipop launched in 2018. First year revenue: $852,000. Forty grocery stores in Northern California.

By 2022: $73.4 million.

By the first half of 2023: $100 million.

By the end of 2024: $400 million. Profitable. Over 50,000 stores. Valued at $1.85 billion after a Series C led by JP Morgan.

From under $1 million to $400 million in six years. That's a 469x increase. In beverages. In a category that didn't exist when they started.

Olipop controls 60% of the global prebiotic/probiotic soda market. Eighteen flavours. Nine grams of prebiotic fibre per can (this matters, and we'll come back to it). Its OLISMART proprietary blend uses multiple fibre sources: chicory root inulin, cassava root fibre, Jerusalem artichoke inulin, nopal cactus. One in four Gen Z consumers in the US drinks Olipop. Half of its growth comes from legacy soda drinkers switching over.

Both Coke and Pepsi came knocking. Goodwin said no. In 2023, he told CNBC: "Right now, my focus is on blowing business through the roof."

As of late 2024, Olipop's co-founders appear to have been replaced by professional management. David Lester has no active role. The company raised $50 million in early 2025 despite being profitable. In investor circles, a late-stage raise when you're already cash-flow positive usually signals one thing: founders taking money off the table. The publicly stated reason was "future growth."

Olipop is currently the largest independent non-alcoholic beverage brand in the United States by dollar sales and unit growth.

Poppi: The $1.95 Billion Exit

Poppi's origin story is simpler. Allison and Stephen Ellsworth created "Mother Beverage" in 2015, appeared on Shark Tank in 2018, got $400,000 from Rohan Oza (the investor behind Vitamin Water) for 25% equity, rebranded to Poppi in 2020, and started growing fast.

Revenue in 2024: $500 million. Available in 36,000+ retail locations across 120 US retailers. 811 employees.

On March 17, 2025, PepsiCo announced the acquisition for $1.95 billion ($1.65 billion net of tax benefits). At 3.9x revenue, it was one of the largest acquisitions in the healthy beverage space. For Rohan Oza's venture fund CAVU, it was arguably their most profitable return ever.

But Poppi has a problem. Each can contains only 2 grams of prebiotic fibre. Olipop has 9 grams. The science says you need at least 5 grams daily for meaningful gut health benefits, and most research uses 7.5 grams or more.

In May 2024, a California woman named Kristin Cobbs filed a class-action lawsuit alleging Poppi's "Be Gut Happy. Be Gut Healthy" slogan was false advertising. The suit argued you'd need to drink more than four cans a day for 21 consecutive days to see any benefit. It also pointed out that the sugar in those four cans would likely offset whatever prebiotic benefit you got.

Poppi settled for $8.9 million in March 2025. They admitted no wrongdoing but quietly dropped the gut health slogan. Co-founder Allison Ellsworth said at the 2024 Beverage Forum that most consumers drink Poppi for the taste, not the function. Fascinating admission from a company that built its entire brand on gut health claims.

PepsiCo bought it anyway. Because PepsiCo wasn't buying a gut health company. They were buying shelf space in a category growing at 300% annually, and a brand with $500 million in revenue and cultural momentum among Gen Z.

Simply Pop: The $47 Billion Gorilla Enters

Coca-Cola launched Simply Pop in February 2025. Five fruit flavours. $2.49 per can. Six grams of prebiotic fibre (triple Poppi, less than Olipop). No added sugar. Vitamin C and zinc. Shelf-stable.

The move was Coke's first attempt at functional soda. They'd been watching the space for years. They reportedly explored acquiring Poppi in 2024 but couldn't close. So they built their own, leaning on the Simply juice brand's 24 years of consumer trust and Coke's distribution muscle.

The category had only 20% market penetration at launch. That's 80% of potential consumers who haven't tried a prebiotic soda yet. For a company that did $47 billion in revenue in 2024, that's a rounding error's worth of investment for a massive growth category.

But Coke has failed at trend-chasing before. Coke Spiced lasted six months. Aha sparkling water got its distribution slashed within two years. Coca-Cola Energy was pulled from North America after barely a year. Simply Pop could be different. It could also be the latest corporate me-too launch that consumers see through.

The digestive health soft drink category grew from $197 million in the US in 2020 to roughly $440 million in 2024. The prebiotic soda market is projected to hit $1 billion by 2030. Small against the $220 billion global soda market. But growing faster than almost anything else in beverages.

The Unit Economics Breakdown

Here's where it gets interesting. The five gut health formats have completely different economic profiles.

Prebiotic Soda (Olipop, Poppi, Simply Pop)

Production cost per can: roughly $0.40 to $0.50. Carbonated water, prebiotic fibre, natural flavours, sweetener (stevia or monk fruit), canning. The glass bottle ($0.12) and co-packer assembly ($0.08) are the biggest line items. Retail: $2.49 per can. Gross margin: around 80%. The killer advantage: shelf-stable. No cold chain. No refrigeration until opened. Fast production cycle. High velocity. CPG dream format.

Kombucha (Remedy, GT's, Batchwell)

Production cost per bottle: $0.75 to $1.25 at scale. Higher than prebiotic soda because of fermentation time (7 to 30 days), cold chain logistics, and shorter shelf life. Retail: $3 to $6 single serve. Gross margin: 60% to 75% depending on scale. The structural problem: cold chain is expensive, fermentation is slow, and the taste profile limits the addressable market. Kombucha built the category. Prebiotic soda will eat its lunch.

Powder (Moodi, AG1)

Production cost per serve: estimated $1 to $2. Ingredients (probiotic strains, prebiotic fibre, natural flavours, sweetener) are cheap in bulk. Branded probiotic strains (HOWARU, LactoSpore) have licensing costs but remain modest at scale. Retail: $2 to $4 per serve depending on bundle and subscription pricing. AG1 charges $79/month for 30 serves ($2.63 per serve). Moodi's tubs are roughly $50 for 20 serves ($2.50 per serve). Gross margin: 70% to 85%. D2C margin monster. No cold chain. Shelf-stable. Lightweight to ship. Subscription model drives retention. The trade-off: you need a shaker, water, and a routine. Less impulse, more commitment.

Gummies

Production cost per serve: estimated $0.15 to $0.30. Gelatin or pectin base, active ingredients, flavouring. Incredibly cheap to manufacture at scale. Retail: $0.50 to $1.00 per serve. Gross margin: 70% to 80%. Shelf-stable. Impulse-friendly. Tastes like candy. The trade-off: lower perceived efficacy. Hard to pack meaningful doses of prebiotics or probiotics into a gummy. The format works for vitamins where doses are tiny. It's harder for fibre, where you need grams, not milligrams. But it's growing fast, particularly in the women's health segment. Moodi launched gummies in 2024.

Capsules

Production cost per serve: the lowest of any format. A few cents per capsule. Retail: $0.30 to $1.00 per serve depending on brand and strain. Gross margin: 80%+. But the market is commoditised. Amazon has turned this into a price war. No brand moat. No lifestyle positioning. No TikTok moment. The supplement aisle is where gut health brands go to become invisible.

The takeaway: prebiotic soda wins on velocity and mainstream scale. Powder wins on margin and D2C retention. Gummies are the dark horse, especially for demographics that hate pills and don't drink soda. Capsules are a race to the bottom. Kombucha is a lifestyle product that will persist but won't dominate.

Moodi: The NZ Case Study

In a market dominated by American behemoths, Moodi is doing something quietly brilliant from Whangaparaoa, New Zealand.

Founded by Kate Gatfield-Jeffries, Moodi launched in May 2022. The brand claims 2,000% growth in its second year. A Seek job listing from today cites 300% year-on-year growth. ZoomInfo estimates revenue at $1 million to $5 million with 10 to 50 employees.

Those aren't Olipop numbers. But Moodi isn't playing Olipop's game.

Moodi is a women's health brand that starts with gut health. Not a gut health brand that happens to market to women. The distinction matters. Their product range tells the story: pre+probiotic powder blends, a sleep hot chocolate, an energy blend, functional protein, electrolytes, and gummies. The common thread isn't the format. It's the customer. Every product is designed for the same woman, at different moments of her day.

The packaging is deliberate. Pastel tones. Clean typography. Instagram-native aesthetic. Sugarcane plastic tubs with a climate-positive carbon footprint. They've reformulated the pre+probiotic blend six times to nail the taste and solubility. The tagline on everything: "Helping hundreds of thousands of women feel their best from the inside, out."

This is not how Olipop thinks. Olipop thinks in SKUs, shelf-feet, and retail velocity. Moodi thinks in rituals, routines, and lifetime value.

The unit economics support it. Moodi sells almost entirely D2C through its website. Free shipping on orders over NZ$79. Subscription-friendly. No slotting fees, no retailer margin share, no cold chain. A tub of pre+probiotic blend is roughly NZ$50 for 20 serves. That's NZ$2.50 per serve, with an estimated COGS of maybe $1 to $1.50. Gross margin in the 60% to 70% range before marketing. Not AG1 levels, but strong for a brand this young.

The marketing engine is TikTok and performance ads. The MagicBrief case study on Moodi describes CPMs on TikTok at half the cost of other platforms. Kate Gatfield-Jeffries won the NZ Woman of Influence Young Leader Award. She's launched a $10,000 Female Founder Grant. The brand has a community, not just customers.

What the operator sees: Moodi understood something most gut health startups miss. You don't need to compete on the soda shelf. You don't need to out-spend Pepsi. You need to own a specific person's daily routine across multiple touchpoints. Powders in the morning. Gummies midday. Sleep blend at night. Electrolytes at the gym. Every product is a retention mechanism for the next one.

Moodi is also the only significant gut health brand in New Zealand with real scale. Olipop isn't here. Poppi isn't here. Simply Pop isn't here. The prebiotic soda format hasn't landed yet. Whoever fills that gap, whether it's Moodi expanding into canned drinks or an Australian brand crossing the Tasman, will have a wide-open market for at least 12 to 18 months.

AG1: The $600 Million Comparison

You can't talk about gut health powders without talking about AG1. Founded in 2010 by Chris Ashenden, a New Zealander who was $5 million in debt from failed real estate investments and had previously gone bankrupt. He spent $35,000 on medical tests, discovered he had nutrient malabsorption issues, and decided to build a supplement that solved his own problem.

AG1 did $600 million in revenue in 2024. Profitable. One product. One SKU. Sold exclusively D2C through its website for $79 a month. Valued at $1.2 billion.

The playbook is worth studying. AG1 targeted podcasters and influencers first. Tim Ferriss. Andrew Huberman. Joe Rogan. Lex Fridman. Lewis Hamilton. The brand became synonymous with the male optimization/biohacker demographic. It's the anti-Moodi in positioning: AG1 is performance fuel. Moodi is daily wellness. Same underlying science (prebiotics, probiotics, functional ingredients). Completely different customer, completely different story.

AG1's structural advantage is its single-SKU discipline. One product. No line extensions for 14 years. That focus is rare and powerful. Every marketing dollar went to the same thing. Every customer conversation was about the same product. Every improvement compounded.

The structural risk is equally clear. Ashenden resigned as CEO in October 2024 amid scrutiny about his past. Kat Cole, the former president and COO, took over. The company is now exploring retail expansion (vending machines, grocery stores, Starbucks partnerships) for the first time. After 14 years of saying no to everything, AG1 is starting to say yes. That's either the right move at the right time, or the beginning of brand dilution.

For operators watching this space, the lesson from AG1 is clean: $600 million in revenue from a single product, sold in a single channel, at $79/month. That's the power of owning a demographic, a daily habit, and a distribution model.

The Structural Reality: Why Only One Wins

The pattern is always the same in consumer categories.

Two survive at scale. One gets acquired. Everyone else dies or niches down.

Beer: InBev and Heineken own the world. Craft beer exists but doesn't threaten the duopoly. Energy drinks: Red Bull and Monster. Everything else is a rounding error (until Celsius carved out a niche by targeting a different demographic). Cola: Coke and Pepsi. Full stop.

Prebiotic soda is following the identical playbook at hyperspeed:

Pepsi bought Poppi for $1.95 billion. Coke launched Simply Pop. Olipop is the last major independent, valued at $1.85 billion with $400 million in revenue. The three-player game is set. Olipop either stays independent (unlikely long-term), goes public, or gets acquired for $3 billion plus.

The structural forces that crush small players in CPG are all present:

Distribution muscle. Getting into 50,000+ retail locations requires relationships, logistics infrastructure, and capital that startups don't have. Coke and Pepsi can put Simply Pop and Poppi in every convenience store, gas station, and supermarket in America within 18 months. An indie brand takes 5 to 10 years to build that footprint.

Slotting fees. Retailers charge to place products on shelves. The fees are enormous. A nationwide rollout in the US can cost tens of millions just in slotting. Before you spend a dollar on marketing.

Promotional budgets. Buy-one-get-one. End-cap displays. Circular ads. Bread and butter of CPG velocity, and they require massive budgets that favour scale players.

Co-packing leverage. Larger brands get better pricing from co-packers because they guarantee volume. A brand producing 10 million cans gets a fundamentally different cost structure than one producing 100,000.

The NZ kombucha market already taught this lesson. Australian-scale Remedy dominates with 40% market share. Local craft brewers like Batchwell and Good Buzz survive but can't challenge the price leader. Banjo Brews and Daily Organics either shut down or are struggling. Scale wins on the shelf. Always.

In D2C supplements, the dynamics are slightly different. Niche brands can survive if they own a specific demographic and build a subscription moat. AG1 owns the male biohacker. Moodi owns the NZ/Australian wellness-focused woman. Seed owns the science-first minimalist. These niches are defensible because the customer relationship is direct, the subscription creates retention, and the brand identity is too specific for Pepsi to copy.

But the floor is rising. AG1 is moving into retail. Amazon is flooded with $15 probiotic capsules. The cost of TikTok ads is climbing. The window for bootstrapped D2C gut health brands to build meaningful scale is narrowing every quarter.

The Science Problem

Here's the part nobody in the industry wants to talk about: the science is shaky.

Poppi just settled a class-action for $8.9 million because its 2 grams of prebiotic fibre per can was "too low to cause meaningful gut health benefits." The plaintiff argued you'd need four cans a day for three weeks to see any potential benefit. The sugar in those four cans would likely undo whatever the prebiotics achieved.

AG1's health claims have been criticised by Dr. JoAnn Manson, professor of medicine at Harvard Medical School, for lacking scientific "rigor." She contrasted AG1's small trials with the kind of 15,000-person, decade-long randomised controlled trials that actually prove something.

None of this has slowed category growth. Consumers want gut health products. Whether those products actually improve gut health is, from a market perspective, almost irrelevant. The health halo sells. The science catches up later. Or doesn't.

But the regulatory risk is real. The Poppi lawsuit set a precedent. If 2 grams of fibre is legally insufficient to claim "gut healthy," where's the line? Olipop's 9 grams is probably defensible. Moodi's 19 billion CFU of clinically studied probiotics gives them a stronger scientific foundation than most beverage brands. But Simply Pop's 6 grams? Poppi's 2 grams under PepsiCo's ownership? The next lawsuit is already being drafted somewhere.

The brands that survive long-term will be the ones with enough active ingredient to withstand regulatory scrutiny. Olipop's 9 grams of fibre. Moodi's 19 billion CFU with named strains (HOWARU Calm, LactoSpore). The brands selling vibes with trace amounts of prebiotics will eventually get caught. The $8.9 million settlement was pocket change for a brand that just sold for $1.95 billion. The next lawsuit, against the next brand, in a more aggressive regulatory environment, might not be so cheap.

White Space: Where The Money Is

The gut health gold rush is nowhere near over. Here's where the economics are most interesting for operators, founders, and investors.

1. Postbiotics: The Next Wave

Probiotics are live bacteria. Prebiotics are the fibre that feeds them. Postbiotics are the bioactive compounds produced by probiotics after they've done their work: short-chain fatty acids, peptides, enzymes.

The operator advantage is structural. Postbiotics don't need to be alive. No refrigeration. No viability concerns. No "store them wrong and they die" problem that plagues every probiotic on the market. Heat-stable. pH-stable. Easier to formulate into anything.

The postbiotics market was $1.6 billion in 2024, growing at 7.4% annually to reach $2.5 billion by 2030. Small compared to probiotics, but the category is where probiotics were 10 years ago. ADM surveyed over 1,000 consumers and found that when people were given a clear explanation of what postbiotics are, 80% said they'd prefer a postbiotic over a probiotic.

Nobody has built a consumer-facing postbiotic brand yet. It's all ingredient suppliers and B2B players. Whoever builds the "Olipop of postbiotics" has a wide-open field.

2. The Gut-Brain Axis: Premium Positioning

The connection between gut health and mental wellbeing is the single most valuable positioning play in functional food. Moodi is already here. Their HOWARU Calm probiotic strain is specifically positioned around the gut-brain axis: stress support, mood balance, sleep quality.

Clinical research presented at Probiota 2025 showed specific biotic interventions improving symptoms associated with stress resilience and sleep quality through defined metabolic pathways.

The white space is format innovation around the gut-brain connection. Functional drinks for stress. Evening blends for sleep. Daytime blends for focus. Nobody owns this at scale. A dedicated gut-brain brand with the right format and science could carve out a defensible premium position.

3. Kids' Gut Health: Massively Underserved

The kids' supplement market is enormous and growing. The gut health segment for children is barely developed. Most probiotic products for kids are either capsules (that kids won't swallow), unflavoured powders (that kids won't drink), or gummy vitamins with trace amounts of probiotics (that parents don't trust).

The white space: a kids' gut health brand built around gummies and powder sachets, with kid-friendly flavours, clear dosing, and clinical strains. Parents will pay a premium for anything that makes their kid healthier. Kids' products have high repeat purchase rates because dosing is daily. Nobody is doing this well.

4. NZ/ANZ Prebiotic Soda Gap

Olipop, Poppi, and Simply Pop are all US-only. The prebiotic soda format has not arrived in New Zealand or Australia in any meaningful way. Kombucha still dominates the "healthy carbonated drink" shelf.

The white space: a shelf-stable prebiotic soda designed for the NZ/Australian market. Priced at $3 to $4 per can. Positioned as the upgrade from kombucha, not a replacement for Coke. The first mover who gets national distribution through Countdown and New World has a 12-to-18-month window before the US brands or Australian competitors arrive.

Moodi could do this. They have the brand, the manufacturing relationships, and the customer base. Whether they choose to move into canned beverages or stay focused on powders and gummies will be one of the more interesting strategic decisions in NZ functional food over the next year.

5. Functional Food Integration: The Invisible Probiotic

The long game isn't standalone products. It's embedding probiotics and prebiotics into foods people already eat. Bread. Cereal. Snack bars. Yogurt (Danone figured this out decades ago). Chocolate. Peanut butter.

Spore-forming probiotics and microencapsulation technology now allow live strains to survive baking, cooking, and extended shelf life. The consumer doesn't need to know the probiotics are in there. They just need to see "supports gut health" on the packaging of something they were already going to buy.

The white space for NZ operators: functional bakery products, snack bars, or breakfast cereals with embedded prebiotics. The COGS uplift is minimal (a few cents per serve for prebiotic fibre). The margin uplift from the health claim is significant. Not sexy. Structurally sound.

6. B2B Ingredient Supply: The Picks and Shovels

During a gold rush, sell shovels.

The real winners might not be the consumer brands at all. They might be the ingredient suppliers. IFF (International Flavors & Fragrances) supplies HOWARU probiotic strains. ADM makes prebiotic fibres and postbiotic ingredients. Sabinsa Corporation makes LactoSpore. These companies supply every brand in the category. When Olipop sells a can, the fibre supplier gets paid. When Moodi sells a tub, the strain supplier gets paid.

The economics are excellent. B2B ingredient supply has recurring revenue, long-term contracts, and switching costs (brands can't easily swap probiotic strains without reformulating and redoing clinical validation). It's the infrastructure layer of a $114 billion market.

The white space for NZ: contract manufacturing and ingredient blending for ANZ gut health brands. As the category grows in this region, brands will need local manufacturing partners who understand the regulatory environment (Medsafe, MPI, HACCP accreditation). Moodi blends locally at an MPI-approved facility. As more brands follow, the demand for local capability grows.

7. Personalised Gut Health: The Premium Frontier

Microbiome testing is already available. At-home gut microbiome tests sequence your gut bacteria and recommend specific probiotic strains, dietary changes, and supplement protocols. The science is developing. The consumer interest is huge.

The white space: a personalised gut health subscription that combines testing with custom-formulated supplements. Test your microbiome. Get a monthly blend formulated for your specific gut profile. Adjust quarterly based on retest results.

The economics: high upfront cost (test kit and initial consultation) with a high-margin recurring subscription. Customer lifetime value would be enormous because the product is literally personalised. Churn would be lower than generic supplements because the switching cost is a new test.

Not for everyone. But for the segment willing to pay $100 to $200/month for optimised health (the same segment buying AG1 at $79/month), it's an obvious next step.

The Lesson

If you're building in this space, the framework is simple: pick your format, pick your demographic, pick your distribution.

You can't be everything. Olipop won prebiotic soda by being a soda company that happens to have prebiotics. Not a health company that makes soda. The branding is nostalgic. The flavours are Root Beer, Vintage Cola, Cream Soda. It sits next to Coke in the fridge, not next to the kombucha. That positioning is the entire business.

Moodi is winning in NZ by being a women's wellness brand that starts with gut health. Not a gut health brand that markets to women. The difference is subtle but structural. Every new product (sleep blend, protein, electrolytes) strengthens the brand rather than diluting it.

AG1 won the powder format by being a daily ritual for optimisation-obsessed men. One product. One channel. $600 million.

The economics work across formats. COGS are low. Margins are high. The ingredients are cheap. What's expensive is attention, distribution, and trust.

The gut health market is $114 billion and growing at 8% to 14% annually depending on the segment. But market size doesn't mean market opportunity for everyone. It means opportunity for the brands that pick a lane and dominate it.

The brands that try to be the "gut health brand" without specifying for whom, in what format, through what channel, will burn through cash and die. The brands that own a specific customer, in a specific format, with a specific story, will build something durable.

The fridge is getting crowded. The supplement shelf is getting crowded. But the right niches are wide open.

Shoutout to the legends whose work informed this piece:

CNBC | CNBC | CNBC | CNBC | Food Dive | Food Dive | Food Dive | Fortune | Fortune | Fortune | BevNET | The Food Institute | Tap Twice Digital | Tap Twice Digital | ClassAction.org | Wikipedia | Wikipedia | MagicBrief | TikTok for Business | Moodi | Moodi | Spacefor | Coca-Cola | The New Consumer | Pati Group | FoodNavigator | FoodNavigator | SupplySide| WholeFoods Magazine | Towards Healthcare | Polaris Market Research | Persistence Market Research | Beverage Industry | Femfounded | Beverage Daily | Financial Models Lab